Use of dupilumab to manage a grade 3 cutaneous adverse effect from enfortumab vedotin/pembrolizumab treatment in a patient with metastatic urothelial carcinoma
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-02-01
|
| Series: | JAAD Case Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S235251262400417X |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850032254378573824 |
|---|---|
| author | Maura C. Gillis, BA Vanessa R. Weir, BA Cecilia Lezcano, MD Gopa Iyer, MD Allison Gordon, MD |
| author_facet | Maura C. Gillis, BA Vanessa R. Weir, BA Cecilia Lezcano, MD Gopa Iyer, MD Allison Gordon, MD |
| author_sort | Maura C. Gillis, BA |
| collection | DOAJ |
| format | Article |
| id | doaj-art-708d8366c0c94d88aa7d090b94ca467d |
| institution | DOAJ |
| issn | 2352-5126 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | JAAD Case Reports |
| spelling | doaj-art-708d8366c0c94d88aa7d090b94ca467d2025-08-20T02:58:41ZengElsevierJAAD Case Reports2352-51262025-02-0156404410.1016/j.jdcr.2024.10.019Use of dupilumab to manage a grade 3 cutaneous adverse effect from enfortumab vedotin/pembrolizumab treatment in a patient with metastatic urothelial carcinomaMaura C. Gillis, BA0Vanessa R. Weir, BA1Cecilia Lezcano, MD2Gopa Iyer, MD3Allison Gordon, MD4Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New YorkDermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New YorkDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New YorkGenitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Medicine, Weill Cornell Medical College, New York, New YorkDermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Correspondence to: Allison Gordon, MD, Dermatology Service, Department of Medicine, David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, 530 E 74th St, New York, NY 10021.http://www.sciencedirect.com/science/article/pii/S235251262400417Xbullousdupilumabenfortumab vedotinflexuraloncodermatologypembrolizumab |
| spellingShingle | Maura C. Gillis, BA Vanessa R. Weir, BA Cecilia Lezcano, MD Gopa Iyer, MD Allison Gordon, MD Use of dupilumab to manage a grade 3 cutaneous adverse effect from enfortumab vedotin/pembrolizumab treatment in a patient with metastatic urothelial carcinoma JAAD Case Reports bullous dupilumab enfortumab vedotin flexural oncodermatology pembrolizumab |
| title | Use of dupilumab to manage a grade 3 cutaneous adverse effect from enfortumab vedotin/pembrolizumab treatment in a patient with metastatic urothelial carcinoma |
| title_full | Use of dupilumab to manage a grade 3 cutaneous adverse effect from enfortumab vedotin/pembrolizumab treatment in a patient with metastatic urothelial carcinoma |
| title_fullStr | Use of dupilumab to manage a grade 3 cutaneous adverse effect from enfortumab vedotin/pembrolizumab treatment in a patient with metastatic urothelial carcinoma |
| title_full_unstemmed | Use of dupilumab to manage a grade 3 cutaneous adverse effect from enfortumab vedotin/pembrolizumab treatment in a patient with metastatic urothelial carcinoma |
| title_short | Use of dupilumab to manage a grade 3 cutaneous adverse effect from enfortumab vedotin/pembrolizumab treatment in a patient with metastatic urothelial carcinoma |
| title_sort | use of dupilumab to manage a grade 3 cutaneous adverse effect from enfortumab vedotin pembrolizumab treatment in a patient with metastatic urothelial carcinoma |
| topic | bullous dupilumab enfortumab vedotin flexural oncodermatology pembrolizumab |
| url | http://www.sciencedirect.com/science/article/pii/S235251262400417X |
| work_keys_str_mv | AT mauracgillisba useofdupilumabtomanageagrade3cutaneousadverseeffectfromenfortumabvedotinpembrolizumabtreatmentinapatientwithmetastaticurothelialcarcinoma AT vanessarweirba useofdupilumabtomanageagrade3cutaneousadverseeffectfromenfortumabvedotinpembrolizumabtreatmentinapatientwithmetastaticurothelialcarcinoma AT cecilialezcanomd useofdupilumabtomanageagrade3cutaneousadverseeffectfromenfortumabvedotinpembrolizumabtreatmentinapatientwithmetastaticurothelialcarcinoma AT gopaiyermd useofdupilumabtomanageagrade3cutaneousadverseeffectfromenfortumabvedotinpembrolizumabtreatmentinapatientwithmetastaticurothelialcarcinoma AT allisongordonmd useofdupilumabtomanageagrade3cutaneousadverseeffectfromenfortumabvedotinpembrolizumabtreatmentinapatientwithmetastaticurothelialcarcinoma |